Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646900 | 0.98 | TSHR (0.43) | TSHRCYP2C19ALDH1A1LMNAELANE | |
| SCHEMBL645426 | 0.98 | TSHR (0.43) | TSHRCYP2C19ALDH1A1LMNAELANE | |
| Acrylic Acid SCHEMBL15775512 | 0.97 | CYP2C19 (0.42) | TSHRCYP2C19ALDH1A1LMNAELANE | |
| Acrylic Acid SCHEMBL4888290 | 0.95 | CYP2C19 (0.43) | TSHRCYP2C19ALDH1A1LMNAELANE | |
| SCHEMBL645585 | 0.94 | TSHR (0.43) | TSHRCYP2C19ALDH1A1LMNAELANE | |
| SCHEMBL14842784 | 0.90 | TSHR (0.50) | TSHRALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL4940905 | 0.90 | TSHR (0.50) | TSHRALDH1A1LMNAKMT2AMAPT | |
| Acrylic Acid Ethyl Ester SCHEMBL28834563 | 0.88 | KMT2A (0.44) | CYP2C19ALDH1A1LMNAELANEKMT2A | |
| SCHEMBL1684006 | 0.87 | TSHR (0.39) | TSHRCYP2C19ALDH1A1LMNAELANE | |
| SCHEMBL1079138 | 0.87 | CYP2C19 (0.42) | TSHRCYP2C19ALDH1A1LMNAELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875265-B2 | A cosmetic composition comprising a specific block polymer and a specific plasticizer intended to be applied to human keratinous substances, such as the skin, lips, eyelashes, eyebrows, nails or hair; film-forming acrylic polymers containing a plasticizer; flexibility; good hold; transfer-free | L'OREAL (FR) | 2011-01-25 | — | — | US | disclosed |
| US-20060147403-A1 | Non-transfer cosmetic composition comprising a sequenced polymer | L'OREAL C.A. | 2006-07-06 | — | — | US | disclosed |
| US-20060134044-A1 | Cosmetic composition comprising a sequenced polymer and a plasticizer | L'OREAL (FR) | 2006-06-22 | — | — | US | disclosed |
| US-20060127334-A1 | Lipstick comprising a sequenced polymer | L'OREAL S.A. (FR) | 2006-06-15 | — | — | US | disclosed |
| CN-1504488-A | Block copolymers and cosmetic compositions containing such polymers | �ź㴫 | 2004-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060147403-A1 | Non-transfer cosmetic composition comprising a sequenced polymer | KRT18, CUTA, LMNB2 | TSHR 4399/4885CYP2C19 3727/4885ALDH1A1 3889/4885 |
| US-20060134044-A1 | Cosmetic composition comprising a sequenced polymer and a plasticizer | NFKB1, NFKB2, POLL | TSHR 3325/4885CYP2C19 3531/4885ALDH1A1 2665/4885 |
| US-20060127334-A1 | Lipstick comprising a sequenced polymer | LIPC, LIPA, LARP7 | TSHR 4549/4885CYP2C19 3015/4885ALDH1A1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.